Io­n­is widens eplon­ter­sen agree­ment with As­traZeneca; In­ozyme looks to get $60M in pub­lic of­fer­ing

As­traZeneca is pay­ing $20 mil­lion to Io­n­is to gain com­mer­cial­iza­tion rights in Latin Amer­i­ca for a drug wait­ing for the FDA’s sig­noff.

Io­n­is said Fri­day morn­ing that it ex­pand­ed its col­lab­o­ra­tion with the UK phar­ma for eplon­ter­sen, an an­ti­sense drug that is be­ing test­ed for hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy (AT­TRv-PN), a neu­rode­gen­er­a­tive dis­ease.

In 2021 As­traZeneca gave Io­n­is $200 mil­lion up­front with the po­ten­tial for up to $485 mil­lion in de­vel­op­ment mile­stones and up to $2.9 bil­lion in sales mile­stones. The deal gave the drug­mak­er the rights to the drug out­side the US, ex­clud­ing cer­tain coun­tries in Latin Amer­i­ca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER